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Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease that results in 
progressive loss of motoneurons, motor weakness and death within 3–5 years after disease 
onset. Therapeutic options remain limited despite substantial number of approaches that have 
been tested clinically. Many neurotrophic growth factors are known to promote the survival of 
neurons and foster regeneration in the central nervous system. Various neurotrophic factors 
have been investigated pre-clinically and clinically for the treatment of ALS. Although pre-clinical 
data appeared promising, no neurotrophic factors succeeded yet in a clinical phase III trial. In 
this review we discuss the rationale behind those factors, possible reasons for clinical failures, 
and argue for a renewal of hope in this powerful class of drugs for the treatment of ALS.
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(Dupuis et al., 2004; Bacman et al., 2006; Martin, 2006), or the cell 
nucleus (Kinoshita et al., 2009). On the molecular level, a lot of pos-
sible culprits have been followed including glutamate excitotoxicity 
(Corona et al., 2007), reactive oxygen species (Carter et al., 2009), 
lipid metabolism (Dupuis et al., 2008a), and others.
Currently, the only available treatment option is riluzole that 
prolongs life by 2–3 months, with questionable functional improve-
ment (Miller et al., 2007). The broad spectrum of molecular and 
cellular players in ALS obviously makes drug development difficult. 
We argue that in the absence of one specific causative mechanism 
identified, protection of the motoneuron with multipotent growth 
factors remains the most rational approach available.
Discovery anD activities of Growth factors
The story of growth factors in the nervous system was started 
by Rita Levi-Montalcini, Viktor Hamburger, and Stanley Cohen 
with the discovery of the nerve growth factor (NGF) in the 1950’s 
(Levi-Montalcini and Hamburger, 1951; Levi-Montalcini et al., 
1954;  Cohen  and  Levi-Montalcini,  1957;  Levi-Montalcini  and 
Cohen, 1960), for which Levi-Montalcini and Cohen received the 
Nobel prize in 1986. Interestingly, the Nobel prize in Medicine and 
Physiology was awarded for the “discovery of growth factors”, which 
at that time already acknowledged the scope of their work for open-
ing up a large area of research and potential therapeutic approaches. 
Presently, the group of proteins regarded as neurotrophic growth 
factors has immensely grown, and a lot has been learned about 
common and specialized activities of these factors. Some of them, 
the neurotrophins, were first described as acting on neuronal cells, 
whereas others, more recently described neurotrophic factors, were 
initially discovered in a non-neuronal context.
Neurotrophic growth factors have an array of activities in the 
nervous system that consist of functions in development, plasticity, 
neurogenesis, disease and injury. Today it is clear that these activities 
aLs: a muLtifaceteD Disease
Amyotrophic lateral sclerosis (ALS) is an incurable fatal motoneu-
ron disease with a lifetime risk of 1:800. It is characterized by pro-
gressive weakness, muscle wasting and death ensuing 3–5 years after 
diagnosis (Mitchell and Borasio, 2007). Since the first description 
of ALS by Charcot, around 150 years ago, and despite tremen-
dous work, the cause(s) of ALS remain(s) unclear. A number of 
genes have been identified that, when mutated, cause familial ALS 
(Valdmanis et al., 2009). In addition, several polymorphisms have 
been identified that pose a genetic risk of developing sporadic ALS 
(Dunckley et al., 2007; Schymick et al., 2007). From these data, 
and a wealth of pre-clinical and clinical investigations it is clear 
that the etiopathogenesis and pathophysiology of ALS is complex 
with many players involved that lead to the functional decline of 
the motor pathway (Pasinelli and Brown, 2006; Rothstein, 2009). 
On the tissue level, it is clear that cells beyond motoneurons are 
involved in ALS pathophysiology. This involves astrocytes, which 
are reactive and apparently toxic in ALS (Schiffer et al., 1996; Nagai 
et al., 2007; Blackburn et al., 2009). Also, reactive microglia and 
protective T-cell infiltration have been noted as players in non-
cell-autonomous toxicity (Engelhardt and Appel, 1990; Xiao et al., 
2007; Beers et al., 2008). On the motoneuron level, it is a matter of 
ongoing research where the disease process is initiated, candidates 
being the neuromuscular junction (NMJ) (Fischer et al., 2004), 
the axon (Collard et al., 1995; Strom et al., 2008), mitochondria 
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Indeed, delivering BDNF with this method leads to a detectable 
level of BDNF in the cerebrospinal fluid, especially at the lumbar 
level (Ochs et al., 2000). The method being feasible, two clinical 
trial were conducted in 2003 and 2005. In 2003, eleven ALS patients 
were enrolled in a trial to receive an intrathecal delivery of BDNF. 
Another trial with intrathecal delivery was conducted in 2005 with 
13 patients (Kalra et al., 2003; Beck et al., 2005). Both trials were 
too small to detect any meaningful efficacy signal.
The failure of BDNF in clinical trials could be explained by 
several reasons. First of all, it remains controversial if and to what 
degree BDNF passes the BBB (Pardridge et al., 1994; Poduslo and 
Curran, 1996; Pan et al., 1998), rendering it problematic to treat the 
spinal cord by subcutaneous delivery. The lack of any efficacy signals 
in the relatively small number of patients treated by direct delivery 
of BDNF to the central nervous system (CNS) might however point 
to additional problems. The second concern with BDNF is that 
it might not have been the most ideal growth factor to test clini-
cally. It appears that BDNF could have the potential to exacerbate 
the disease to some extent, as p75, a receptor for BDNF, appears 
involved in ALS pathophysiology (Lowry et al., 2001; Dupuis et al., 
2008b). Indeed, when p75 is not bound to trk receptors, it might 
induce apoptosis in both animal models of ALS and patients. A 
report in 2004 actually showed that an antagonist for p75 slows 
progression of ALS in SOD-1 animals (Turner et al., 2004). Thus, 
the potential beneficial effect of BDNF could be concealed by the 
concomitant activation of pro-apoptotic pathways through the p75 
receptor. Doubts in the suitability of BDNF for ALS treatment are 
also supported by animal experiments conducted after the clinical 
trials. A study performed on SOD-1 transgenic mice using a gene 
therapy approach with BDNF among others neurotrophic factors 
(Park et al., 2009) could not observe any positive effects of BDNF 
neither on disease progression nor on survival, questioning the 
rationale for clinical trials with BDNF in ALS.
ciLiary neurotrophic factor
After the discovery of NGF, a number of other, unrelated growth fac-
tors in the nervous system were discovered, that have a similar scope 
of activities, but do not belong to the group of “neurotrophins” in 
its restricted sense. The most well-known of these are the Ciliary 
neurotrophic factor (CNTF) (Lin et al., 1989) and the glial cell-line 
derived neurotrophic factor (GDNF) (Lin et al., 1993). The history 
of CNTF in ALS is similar to the one of BDNF. CNTF was one of the 
earliest neurotrophic factor shown to have a direct neuroprotective 
effect on degenerating motoneurons in stress-induced conditions 
(Table 1). Two studies in 1990 demonstrated that CNTF protects 
motoneurons in cell culture (Arakawa et al., 1990), and in vivo after 
axotomy-induced apoptosis in the rodent (Sendtner et al., 1990). 
Those results were strengthened by the beneficial effect of CNTF in 
a mouse model of neuronopathy with motoneuron degeneration 
(Sendtner et al., 1992b), and by increased vulnerability of spinal 
motoneurons in a knock-out mouse line for CNTF (Masu et al., 
1993). These results were published in the early 90s, prior to the 
development of mutated super oxide dismutase 1 (SOD-1) trans-
genic mice in 1994 (Gurney et al., 1994), today the most frequently 
employed mouse model for ALS. Because of these promising effects 
on motoneurons, CNTF went directly to the clinic, and became 
the first growth factor investigated clinically for ALS. Two clinical 
are reaching far beyond the original “neurotrophic theory”, which 
postulated that only neurons that encounter these tissue target-de-
rived factors in a critical phase of their development will survive, and 
that the availability of limited amounts of survival factors is a key 
factor in the development of the nervous system and other organs.
One essential activity of these factors is an intrinsic autocrine 
survival effect that is modulated during development (Lamballe 
et al., 1994; Valdes-Sanchez et al., 2010). Other effects are stimula-
tion of neurite outgrowth and axon guidance (Tuttle and O’Leary, 
1998; Huang and Reichardt, 2003), securing correct connectivity 
in the brain and spinal cord. Moreover, growth factors in the nerv-
ous system influence dendrite and synapse formation, thus directly 
impacting on plasticity mechanisms (Lo, 1998; Vicario-Abejon et 
al., 2002). An additional basic activity of many growth factors in the 
nervous system are influences on the proliferation, migration and 
differentiation of stem cells in the developing and adult nervous sys-
tem (Cattaneo and McKay, 1990; Kuipers and Bramham, 2006).
These basic properties are also employed by the nervous system 
in the case of disease and injury, and thus constitute a powerful 
endogenous repair and maintenance system. The potential for a 
therapeutic application of these factors has been realized early on, 
and the last two decades have seen a number of approaches to 
exploit this potential in several neurological disorders, one of the 
most prominent being ALS. In the following we review growth fac-
tors that have been studied pre-clinically and clinically in ALS.
Brain-DeriveD neurotrophic factor
Brain-derived  neurotrophic  factor  (BDNF)  together  with  the 
related factors NGF, Neurotrophin-3 (NT-3), and Neurotrophin-
4/5 (NT-4/5) belongs to the group of “Neurotrophic factors” or 
“Neurotrophins”, which constitute the most narrowly defined and 
oldest group of nervous growth factors. This narrow definition is 
justified as these factors are all related to the first member of that 
family (NGF), and share related receptors (trkA,B,C; p75NTR). 
BDNF  is  historically  the  second  neurotrophic  factor  directly 
described as such (Barde et al., 1982). Several groups published 
promising results on rescuing axotomized motoneurons (Sendtner 
et al., 1992a,b; Yan et al., 1992; Gimenez y Ribotta et al., 1997) and 
on improving the phenotype of wobbler mutant mice (Ikeda et al., 
1995), a model for motoneuron disorders (Table 1). In addition, 
BDNF protects neurons from in vivo excitotoxicity (Bemelmans et 
al., 2006), a mode of action of relevance to ALS.
Several clinical studies were conducted after those encouraging 
data (Table 3). More than 1000 patients were enrolled in a trial 
published in 1999 (The BDNF Study Group (Phase III) 1999). In 
this trial, the tolerability of BDNF was shown to be better than of 
Ciliary neurotrophic factor (CNTF), despite some adverse effects 
such as diarrhea. While the results failed to show an amelioration 
for patients’ condition or survival after treatment with BDNF, it 
appeared that a subgroup of patients responded positively to the 
treatment and demonstrated a higher survival rate. This subgroup 
consisted of patients having the lowest vital capacity and receiving 
the highest dose of BDNF, suggesting that BDNF could be benefi-
cial for patients in advanced stages of the disease. The investiga-
tors suggested to use higher doses or intrathecal delivery to deliver 
BDNF to the diseased spinal cord. One year later, a phase 1 trial was 
published, showing the feasibility of intrathecal delivery of BDNF. www.frontiersin.org  June 2010  | Volume 4  | Article 32  |  3
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with rescue of motoneurons after axotomy-induced degeneration 
and numerous positive in vitro data, (Buj-Bello , 1995; Gimenez y 
Ribotta et al., 1997; Bilak et al., 2001; Kosuge et al., 2009). including 
excitotoxity-induced stress (Kosuge et al., 2009). Unlike BDNF and 
CNTF, GDNF effects were tested in SOD-1 animals in a number 
of studies prior to initiation of clinical studies (Table 1). The out-
comes of those studies argued for a benefit of GDNF treatment 
despite several controversial data. GDNF treated motoneurons of 
SOD-1 animals are clearly protected (Mohajeri et al., 1999; Acsadi 
et al., 2002; Li et al., 2007; Suzuki et al., 2007; Park et al., 2009). 
The effects of GDNF on survival and functional outcomes appear 
more problematic, as well as the rescue of neuromuscular junc-
tions. While some studies report a benefit on disease progression 
and/or survival (Mohajeri et al., 1999; Acsadi et al., 2002; Li et al., 
2007), others find no effect on disease progression and integrity 
of neuromuscular junctions (Li et al., 2007; Suzuki et al., 2007; 
Park et al., 2009). With respect to extrapolation to the clinic, it has 
to be mentioned that Park and associates were the only ones who 
initiated treatment at the onset of the disease, and they observed a 
protection of motoneurons but not an increase in survival.
Glial cell-line derived neurotrophic factor has not yet been tested 
clinically for the treatment of ALS patients. Clinical observations 
demonstrated that the level of GDNF is increased in the cerebros-
pinal fluid of ALS patients (Grundstrom et al., 2000), and that its 
receptor is expressed in the spinal cord, even at late stages of the 
disease (Mitsuma et al., 1999). Due to its in vivo neuroprotective 
effects on motoneurons GDNF remains a potential candidate for a 
trials were conducted in 1996 and enrolled 570 and 730 patients, 
respectively (Table 3). The investigators focused mainly on daily 
living activities outcomes and survival (ALS CNTF Treatment Study 
Group, 1996; Miller et al., 1996). Unfortunately, both of those trials 
reported no observable benefit of treatment. Moreover, adverse 
effects, especially for the doses over 5 μg/kg, were severe, leading 
to the cessation of treatment in many patients.
What could be the reasons to explain the lack of efficiency of 
CNTF after such promising pre-clinical outcomes? Apart from pos-
sible general aspects of failure discussed further below (e.g. lacking 
translatability of rodent findings) we see two main specific reasons. 
First of all, it has to be pointed out that despite CNTF’s ability to 
cross the blood-brain barrier (Pan et al., 1999), a pharmacokinetic 
study in the rodent showed that CNTF has a half-life of only 2.9 min 
after intravenous injection. Due to this low half-life, subcutaneous 
application of CNTF appeared not appropriate to target the central 
nervous system. Secondly, the doses used in animals were about 
1 mg/kg, whereas the highest safe dose in the human is 200 times 
lower than that (5 μg/kg). This limited dose and short half-life of 
CNTF could easily account for the inefficiency of CNTF in patients. 
No further clinical projects were pursued with CNTF in ALS after 
these two trials.
GLiaL ceLL-Line DeriveD neurotrophic factor
Glial cell-line derived neurotrophic factor (GDNF) was studied a 
few years later than CNTF and BDNF. As it was the case for the other 
neurotrophic factors, the pre-clinical results were encouraging, 
Table 1 | Listed are classic neurotrophins that have been evaluated in animal models related to ALS. Given are the respective animal model, the 
application mode of the factor, and the outcome of the experiment.
  Model  Treatment (animal/group)  Outcomes  Reference
BDNF  Axotomy, rat  Gel foam, 5 μg (n = 9)  +30% MNs survival  Sendtner et al. (1992a)
  Axotomy, rat  s.c. injection, 5 mg/kg (n = 4)  +30% MNs survival  Yan et al. (1992)
  Axotomy, rat  Viral (n = 4)  +15% MNs survival  Gimenez y Ribotta et al. (1997)
  Excitotoxic lesion, mice  Viral (n = 12)  Neuroprotection  Bemelmans et al. (2006)
  Woobler mice  s.c. injection 5 mg/kg 3 times a  +Motor function  Ikeda et al. (1995)
    week (n = 10)  +Enervation 
  SOD-1G93A mice  Ex vivo, presympt.(n = 18)  No benefit  Park et al. (2009)
CNTF  Axotomy, rat  Gel foam, 5 μg (n = 4)  +55% MNs survival  Sendtner et al. (1990)
  pmn mice  Ex vivo (n = 8)  +MNs  Sendtner et al. (1992b)
     +Motor functions 
     +Survival 
GDNF  Axotomy, rat  Viral (n = 9)  +20% MNs survival  Gimenez y Ribotta et al. (1997)
  SOD-1G93A mice  Ex vivo, presympt. (n = 16)  +Motor functions  Mohajeri et al. (1999)
     +MNs 
     +Atrophy 
  SOD-1G93A mice  Viral, presympt. (n = 17)  +Motor functions  Acsadi et al. (2002)
     +12% survival 
  SOD-1G93A rats  Ex vivo, presympt. (n = 9)  +MNs  Suzuki et al. (2007)
      0 NMJs 
  SOD-1G93A mice  Transgenic, presympt. (n = 31)  +Motor functions  Li et al. (2007)
     +MNs 
     +11% survival 
  SOD-1G93A mice  Ex vivo, presympt. (n = 46)  +MNs, 0 survival  Park et al. (2009)
+: significant benefit; 0: no significant benefit; s.c.: subcutaneous; i.p.: intraperitoneal; presympt.: presymptomatic.Frontiers in Neuroscience  |  Neuropharmacology    June 2010  | Volume 4  | Article 32  |  4
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IGF-1 on muscular strength and survival (Sorenson et al., 2008). 
Unfortunately, IGF-1 treated patients did not improve relative to 
the control patients.
There may be explanations for the lack of success of this trial 
apart from the conclusion that IGF-1 is ineffective in ALS, espe-
cially since clinical observations show that the distribution of 
IGF-1 is increased at the spinal level of ALS patients (Wilczak 
et al., 2003; Corbo et al., 2010). One point of critique against 
the pre-clinical work is that no subcutaneous administration of 
IGF-1 was performed, indeed, only genetic therapies (Kaspar et al., 
2003; Lepore et al., 2007; Dodge et al., 2008; Franz et al., 2009) 
or intrathecal administration (Nagano et al., 2005a) were used to 
treat SOD-1 animals. A genetic approach can not be translated into 
subcutaneous delivery in patients, due to the high and constant 
expression of IGF-1 over time and the intrathecal administration 
which directly delivers IGF-1 to the CNS in contrast to the subcu-
taneous injections studied in the large trials. Also, treatment in the 
SOD-1 model ideally should be started at later time points during 
disease progression, and not before the disease onset.
Indeed, as Howe et al. (2009) observed, it is highly unlikely that 
meaningful levels of IGF-1 were reached in the CSF and CNS tissue 
with the dose of IGF-1 used in the latest clinical trial (Sorenson 
et al., 2008).
vascuLar enDotheLiaL Growth factor
Discovered in the late 80’s as a growth factor for vascular endothelial 
cells, Vascular endothelial growth factor (VEGF) induces endothelial 
cell growth and angiogenesis (Connolly et al., 1989). The first evidence 
for neurotrophic proprieties of VEGF arose in the early 2000’s, with 
studies on neuronal regeneration (Sondell et al., 1999, 2000; Hobson 
et al., 2000). VEGF was implicated as a growth factor possibly involved 
in ALS by the discovery that mice with deletion of the HIF-response 
element in the VEGF promoter developed an ALS-like phenotype 
(Oosthuyse et al., 2001). Subsequent genetic analyses however failed 
to produce clear evidence for an effect of VEGF polymorphisms on 
the risk of developing ALS in the human (Gros-Louis et al., 2003; 
Lambrechts et al., 2003; Van Vught et al., 2005; Chen et al., 2006; 
Fernandez-Santiago et al., 2006; Zhang et al., 2006). However, apart 
from the genetic discussion, VEGF promotes survival of cells over 
expressing a mutated SOD1 G93A protein (Li et al., 2003; Lunn et 
al., 2009) and ameliorates effects of glutamate excitotoxicity (Tolosa 
et al., 2008; Bogaert et al., 2009). In rodents (Table 2), VEGF treat-
ment leads to a delay of disease onset, an improvement of motor 
functions, protection of motoneurons and neuromuscular junctions, 
and increase in survival (Azzouz et al., 2004; Storkebaum et al., 2005; 
Wang et al., 2007; Zheng et al., 2007; Hwang et al., 2009).
These data are promising for a clinical investigation of VEGF in 
ALS. Beside the pre-clinical evidence for a potential benefit of VEGF 
in the treatment of ALS, clinical observations did show that VEGF 
is down regulated in the late stage of ALS (Devos et al., 2004), and 
restoring its level therefore could bring benefit for the patients. The 
potential of VEGF as a therapeutic agent is further strengthened by 
its ability to cross the BBB (Wang et al., 1996; Dobrogowska et al., 
1998; Yang et al., 2009). There are no published clinical trials so far, 
but a clinical trial is ongoing in Belgium and is currently recruiting 
patients. Clearly, angiogenic side effects of VEGF treatment will 
have to be monitored closely.
clinical trial in ALS, despite controversial efficacy data on survival. 
However, as there is evidence that GDNF does not cross the BBB 
(Kastin et al., 2003), a future challenge remains in developing a 
protocol to resolve this issue, such as using an intrathecal delivery 
device for GDNF. Although there were signs of biological efficacy 
of GDNF in Parkinson’s disease (PD) (Gill et al., 2003; Patel et al., 
2005), the further development of direct intracerebral delivery 
in PD was halted by the originator of the drug due to possible 
safety issues.
insuLin-Like Growth factor-1
Beside  the  classic  neurotrophins,  other  growth  factors  (“Non-
classical’’ neurotrophic factors) show prominent neuronal activ-
ity but were first described as acting in other compartments of 
the body. Insulin-like growth factor-1 (IGF-1) has a multitude 
of actions and targets in the body, and the discovery of its effect 
on neurons dates from the end of the 80’s (Shemer et al., 1987). 
Neurons in the central nervous systems express functional recep-
tors of insulin-like growth factor 1 (IGF-1) (Shemer et al., 1987). 
In vitro and in vivo, IGF-1 was able to rescue motoneurons (Caroni, 
1993; Li et al., 1994; Bilak et al., 2001) and to reduce glutamate 
excitotoxicity (Nakao et al., 1996; Vincent et al., 2004). Therefore 
IGF-1 became an interesting drug candidate for ALS.
Several clinical studies with IGF-1 in ALS were conducted early, 
before testing IGF-1 in SOD-1 animals (Table 3). In the late 90’s, 
two investigations were published with different conclusions (Lai 
et al., 1997; Borasio et al., 1998). Lai et al. enrolled 266 patients 
and administrated IGF-1 subcutaneously. The conclusion of the 
investigators were that IGF-1 is safe, slows progression of motor-
impairment, and increases quality of life. In a second trial, Borasio 
et al. enrolled 183 patients with the same mode of administration. 
The investigators focused on disease progression but found no 
improvement after treatment. Indeed, IGF-1 treatment appeared 
to be safe but did not improve quality of life of the patients nor 
motor functions. Additionally, a pilot study was conducted with 
intrathecal delivery of IGF-1 (Nagano et al., 2005b). Investigators 
claimed that the treatment was beneficial for the patients. Two 
groups of patients were compared, receiving high or low doses of 
IGF-1 and it was observed that the motor functions decline was 
slowed down with the high dose of IGF-1 compared to the low 
dose. However, as this study was not placebo-controlled, the results 
should be considered with caution.
Some years later, pre-clinical reports investigating the effects 
of IGF-1 in SOD-1 animals were published (Table 2). The major-
ity of the reports argue in favor of a potential protective effect in 
ALS, with an increase in survival and motor function parameters 
(Kaspar et al., 2003; Dobrowolny et al., 2005; Nagano et al., 2005a; 
Lepore et al., 2007; Dodge et al., 2008; Franz et al., 2009). Also, 
IGF-1 mediates NMJ regeneration in a non-ALS related animal 
model (Apel et al., 2009), although some contradictory results are 
published (Grumbles et al., 2009). Nevertheless, two studies did 
not observe an improvement of survival in the SOD-1 transgenic 
model after IGF-1 treatment (Messi et al., 2007; Franz et al., 2009), 
and the work of Lepore et al. (2007) suggested that IGF-1 effect 
were only observed in male mice. At the same time, a new clini-
cal trial was initiated, with subcutaneous administration of IGF-1. 
This clinical trial enrolled 330 patients and studied the effects of www.frontiersin.org  June 2010  | Volume 4  | Article 32  |  5
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Table 2 | Listed are all non-classical neurotrophic factors that have been evaluated in animal models related to ALS. Given are the respective animal 
model, the application mode of the factor, and the outcome of the experiment.
  Model  Treatment (animal/group)  Outcomes  Reference
IGF-1  Axotomy, mice  Gel diffusion, 5 μg  +40% MNs survival  Li et al. (1994)
   +5-μg injection (n = 4)   
  SOD-1G93A mice  Viral, onset (n = 25)  +motor functions  Kaspar et al. (2003)
     +MNs+30% survival 
  SOD-1G93A mice  Transgenic, presympt. (n = 30)  +motor functions  Dobrowolny et al. (2005)
     +MNs+24% survival 
  SOD-1G93A mice  Intrathecal, 0.1–1 mg/kg/day,  +motor functions  Nagano et al. (2005a)
    presymp. (n = 6)  +MNs 
     +11% survival 
  SOD-1G93A mice  Transgenic, presympt. (n = 10)  No benefit  Messi et al. (2007)
  SOD-1G93A mice  Viral, presymp. (n = 9)  ±motor functions  Lepore et al. (2007)
     ±MNs±survival 
  SOD-1G93A rats  Viral, presymp. (n = 17)  ±motor function  Franz et al. (2009)
     +MNs 
      0 survival 
  SOD-1G93A mice  Viral, onset (n = 25)  +motor functions  Dodge et al. (2008)
     +MNs 
     +11% survival 
VEGF  SOD-1G93A mice  Viral, presympt. (n = 7)  +motor functions  Azzouz et al. (2004)
     +MNs 
     +30% survival 
  SOD-1G93A rats  Pump delivery, 0.2–0.6 μg/kg,   +motor functions  Storkebaum et al. (2005)
    presympt. (n = 17)  +MNs/NMJs 
     +7% survival 
  SOD-1G93A mice  i.p., 1–8 μg/kg, 3 times a week,  +MNs +NMJs  Zheng et al. (2007)
    onset (n = 5)  0% survival 
  SOD-1G93A mice  Ex vivo presympt. (n = 10)  +motor functions  Hwang et al. (2009)
     +9% survival 
  SOD-1G93A mice  Transgenic presympt. (n = 6)  +motor functions  Wang et al. (2007)
     +MNs+17% survival 
FGF  Axotomy, rats  Gel foam, 2.5 μg (n = 48)  +50% MNs survival  Cuevas et al. (1995)
HGF  Axotomy, rats  Gel foam, 35 mg/kg (n = 4)  +ChAT activity  Okura et al. (1999)
  SOD-1G93A mice  Transgenic, presympt. (n = 16)  +motor functions  Sun et al. (2002)
     +MNs 
     +19% survival 
  SOD-1G93A rats   Intrathecal, 200 μg for  +motor functions  Ishigaki et al. (2007)
    4-weeks symp. (n = 8)  +MNs 
     +7 .7% survival 
  SOD-1G93A mice  Transgenic, presympt. (n = 4)  +MNs  Kadoyama et al. (2007)
BMP-7  SOD-1G93A mice  10 μg, once (n = 22)  No benefit  Dreibelbis et al. (2002)
EPO  SOD-1G93A mice  s.c., 33.2 μg/kg/day,   +motor functions  Grignaschi et al. (2007)
    presympt. (n = 11)  0 MNs 
      0% survival 
  SOD-1G93A mice  i.p., 8.3 μg/kg twice a week,   ±motor functions  Grunfeld et al. (2007)
    presympt. (n = 11)  0% survival 
  SOD-1G93A mice  i.p., 41.5 μg/kg twice a month,   +motor functions  Koh et al. (2007)
    presympt. (n = 24)  +MNs 
     +10% survival 
G-CSF  Axotomy, mice  Transgenic (n = 7)  +40% MNs survival  Henriques et al. (2010)
  SOD-1G93A mice  Osmotic pump, 30 μg/kg/day,   +motor functions  Pitzer et al. (2008)
    sympt. (n = 18)  +MNs+7% survival 
+: significant benefit; ±: partial effect; 0: no significant benefit; s.c.: subcutaneous; i.p.: intraperitoneal; sympt.: symptomatic; presympt.: presymptomatic.Frontiers in Neuroscience  |  Neuropharmacology    June 2010  | Volume 4  | Article 32  |  6
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expression of EPO and its receptor in the central nervous system 
(Lewczuk et al., 2000; Siren et al., 2001a,b; Ehrenreich et al., 2004). 
EPO is able to counteract apoptosis of neurons after hypoxia and 
ischemia. It is also able to enhance regeneration of the NMJs in rats 
after crush injury (Toth et al., 2008).
Recently,  EPO  was  tested  in  SOD-1  transgenic  animals 
(Table 2). Three studies were published in 2007 by three differ-
ent groups. All report a beneficial effect of EPO (Koh et al., 2007; 
Grignaschi et al., 2007; Grunfeld et al., 2007). Koh et al. describe 
protection of motoneurons against degeneration and an increase 
in survival of the SOD-1 animals after treatment. In contrast, 
despite a delay on symptom progression, Grignaschi et al. and 
Grunfeld et al. did not observe an extension of survival. Previous 
work on EPO in brain injury demonstrated that EPO is able to 
cross the BBB (Statler et al., 2007), making it a good candidate to 
target the CNS. Especially carbamylated EPO (CEPO) might be a 
good candidate for ALS treatment, as it lacks hematopoietic effects 
of EPO while preserving neuroprotective properties (Leist et al., 
2004; Mennini et al., 2006; Kirkeby et al., 2008). However, more 
pre-clinical work is needed before concluding on the relevance 
of EPO for ALS.
thromBopoietin
Thrombopoietin (TPO) is a glycoprotein involved in the regu-
lation of the thrombocytosis. Recently the receptor for TPO has 
been detected in the central nervous system (Yang et al., 2004). 
In contrast to other hematopoietic factors with neuroprotective 
activity, TPO induces apoptosis in neurons and inhibits neuronal 
differentiation (Ehrenreich et al., 2005; Samoylenko et al., 2008). 
Despite those negative results, the effects of TPO were investigated 
in the SOD-1 transgenic mouse model. TPO did not show any 
benefit in this model (Caraganis et al., 2008).
GranuLocyte-coLony stimuLatinG factor
Granulocyte-colony stimulating factor (G-CSF) is a glycopro-
tein responsible for the generation of neutrophilic granulo-
cytes. G-CSF is currently used clinically in the treatment of 
chemotherapy-induced neutropenia. Recently, neuroprotective 
and regenerative properties in the brain and in the spinal cord 
have been described (Schneider et al., 2005). The G-CSF recep-
tor is expressed in diverse areas of the CNS with a predomi-
nantly neuronal localization, including spinal motoneurons. 
In rodent models for stroke, G-CSF displays anti-apoptotic 
properties. In addition, G-CSF induces neuronal differentia-
tion of neural progenitor cells, and is able to cross the brain 
blood barrier (Schneider et al., 2005). G-CSF enhances neurite 
outgrowth in vitro, and preserves tract integrity in spinal cord 
injury (Pitzer et al., 2010). It also enhances axonal regenera-
tion and muscle reinnervation after axotomy in rodents (Pan 
et al., 2009).
We investigated the effects of G-CSF on animal models of 
motoneuron diseases (Table 2), including axotomized neonatal 
mice (Henriques et al., 2010) and SOD-1 transgenic animals 
(Pitzer et al., 2008). Subcutaneous delivery of G-CSF, as well 
as  transgenic  over  expression,  is  able  to  slow  down  disease 
progression and increase survival of SOD1 mice by rescuing 
motoneurons.
the fiBroBLast Growth factors
The Fibroblast Growth Factors (FGF) proteins are growth factors 
with homologous structure that promote angiogenesis and the 
proliferation of fibroblasts. Members of this family were tested for 
their effects on motoneurons. It was demonstrated that FGF-1 and 
FGF-2 can protect motoneurons after axotomy-induced apopto-
sis, and that they support neuronal regeneration (Cuevas et al., 
1995; Piehl et al., 1995; Klimaschewski et al., 1999) (Table 2). 
However, one recent report points out that, in ALS, FGF-1 might 
activate motoneuron apoptosis by astrocytes, thereby possibly 
contributing to ALS pathophysiology (Cassina et al., 2005). More 
work is needed to establish if the FGFs can be drug candidates 
for ALS.
hepatocyte Growth factor
Hepatocyte Growth Factor (HGF) was discovered in 1984 as a 
growth factor acting on the liver (Nakamura et al., 1984). This 
growth  factor  exerts  anti-apoptotic  activity  in  the  liver  after 
endotoxin-induced hepatic failure (Kosai et al., 1999). Neuronal 
effects consist of activity in the guidance and survival of neurons 
in the developing nervous system (Ebens et al., 1996). Moreover, 
HGF is protective on motoneurons in culture and in vivo after 
axotomy (Wong et al., 1997; Okura et al., 1999). In rodent mod-
els of ALS, HGF reduces motoneuron degeneration and increases 
survival (Sun et al., 2002; Ishigaki et al., 2007; Kadoyama et al., 
2007) (Table 2).
Hepatocyte Growth Factor appears to be a good candidate for 
the treatment of ALS, especially since HGF levels in ALS patients 
appear to be dysregulated (Tsuboi et al., 2002). However, additional 
pre-clinical work is required. Indeed, more insight at the level of 
the neuromuscular junctions is welcome since it seems that HGF 
can have an influence on the formation of the NMJs (Madhavan 
and Peng, 2006; Tatsumi et al., 2009) but appears to be inefficient 
on their regeneration unless used in conjunction with other growth 
factors (Grumbles et al., 2009). It can be also of interest for the 
design of a clinical trial to investigate whether a systemic delivery of 
HGF can reproduce the promising results observed after intrathecal 
administration in rodents.
Bone morphoGenetic proteins
The Bone Morphogenetic Proteins (BMPs) are a family of growth 
factors influencing bone formation. BMPs have potent actions in the 
nervous system (Ebendal et al., 1998). A recent report on a drosophila 
model of ALS suggests an implication of the BMP signaling pathway 
in the pathophysiology of the disease (Ratnaparkhi et al., 2008). Only 
one report on transgenic ALS models was published with one of the 
BMPs, BMP-7 (Dreibelbis et al., 2002). The protocol used to treat 
the mice was certainly ambitious with a single injection of BMP-7 
which likely resulted in the negative outcome of this experiment 
(Table 2). BMPs appear as an interesting growth factor family for 
the treatment of ALS, however, much more work is needed to come 
to a judgement whether BMPS are clinical candidates for ALS.
erythropoietin
The first hematopoietic growth factor identified as a possible neuro-
nal growth factor was Erythropoietin (EPO). Research on its ability 
to counteract effects of hypoxia in general led to the discovery of the www.frontiersin.org  June 2010  | Volume 4  | Article 32  |  7
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2009). Similarly, Zhang et al. (2008) report on a delay in motor 
decline. Another clinical trial used G-CSF indirectly by treating 
ALS patients with an autologous transplantation of hematopoi-
etic stem cells into the   cerebrospinal fluid. The conclusion of the 
investigators was that the treatment results in an improvement 
of the patients’ quality of life and a delay of disease progression 
(Martinez et al., 2009). It is not clear whether the reported benefit 
might be caused by treatment with G-CSF or by the transplantation 
of stem cells, or both.
Curiously, the potential of G-CSF in ALS was investigated in 
patients before our pre-clinical study was published (Table 3). Up to 
now, three clinical pilot studies were conducted with G-CSF in ALS 
patients showing that subcutaneous G-CSF treatment is reasonably 
tolerated in the doses given (Cashman et al., 2008; Zhang et al., 
2008; Nefussy et al., 2009). Effects of G-CSF on disease progres-
sion can not be deduced from these studies since the size of patient 
cohorts was too small. Nevertheless, in one trial, an interesting trend 
for slowing down disease progression was reported (Nefussy et al., 
Table 3 | Given are all growth factors that have been in any clinical trial in ALS patients, inclusion criteria, application modes and doses, and 
outcome.
Trial 
size
Inclusion Treatment Treatment 
duration
Outcomes Adverse 
effects
Reference
CNTF 570 Duration < 3 years, 
only sporadic case
s.c. 0.5–5 μg/kg/
day
6 months No benefit Severe. 
Including death 
Miller et al. 
(1996)
730 / s.c. 15–30 μg/kg 3 
times/week
9 months No benefit Severe, 
including 
weight loss
ALS CNTF 
Treatment 
Study Group 
(1996)
BDNF 1135 FVC, ALSFRS s.c. 25–100 μg/kg/
day
9 months No benefit. 
Trend in high 
dose group.
Tolerable, 
injection site 
reaction
The BDNF 
Study Group 
(Phase III) 
(1999)
11 Definite to probable 
ALS, FVC
Intrathecal, 
25–150 μg/day
4–6 weeks No benefit No side effects Kalra et al. 
(2003)
13 Definite to probable 
ALS
Intrathecal, 
25–150 μg/day
9 months No benefit No side effects Beck et al. 
(2005)
IGF-1 266 Duration > 36 month, 
FVC, AALS score
s.c. 0.05 mg/kg 
once or twice/day
9 months Slow 
decline, 
better life 
quality.
No side effects Lai et al. 
(1997)
183 Duration > 36 months, 
FVC, AALS score
s.c. 0.01 mg/kg/
day
9 months No benefit Weakness, 
injection site 
pain, dyspnea
Borasio et al. 
(1998)
9 Duration > 36 months, 
FVC, Norris scale, in 
progression, age
Intrathecal, 
0.5–3 μg/kg twice 
a month
40 months Slow decline 
of motor 
functions.
Tolerable, mild 
skin eruption.
Nagano et al. 
(2005b)
330 Definite to probable 
ALS, FVC, age, MMT
s.c. 0.05 mg/kg/
twice a day
2 years No benefit Tolerable, 
hypoglycemia
Sorenson 
et al. (2008)
G-CSF 39 Definite to probable 
ALS, FVC
s.c. 5 μg/kg/day 
for 4 consecutive 
days (every 
3 months)
12 months No benefit Tolerable, bone 
and muscle 
pain
Nefussy 
et al. (2009)
13 Confirmed ALS, FVC 2 μg/kg/day  5 days Slow decline Tolerable, mild 
fever
Zhang et al. 
(2008)
10 Confirmed ALS, FVC, 
nutrition state
s.c. 300 μg/day
G-CSF , followed 
by stem cells 
transplantation
3 days Slow 
decline, 
better life 
quality.
Tolerable Martinez 
et al. (2009)
s.c.:subcutaneous.Frontiers in Neuroscience  |  Neuropharmacology    June 2010  | Volume 4  | Article 32  |  8
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In all major clinical trials done so far, this was not the case, or 
has not been investigated. Examples for that include BDNF, CNTF 
and IGF-1. For CNTF, the dose showing benefit for motoneurons 
in vivo was three orders of magnitude lower in the human case. In 
addition, s.c. injected CNTF has a plasma half-life time of only a 
few minutes, and does not reach the target tissues. A similar sce-
nario can be drawn for BDNF, with questionable delivery of the 
growth factors to the CNS. For IGF-1, CSF levels reached with the 
chosen subcutaneous dose of 0.05 mg/kg bid likely are more than 
an order of magnitude below endogenous levels in the CSF, and 
thus therapeutically meaningless (Howe et al., 2009).
proBLems with cLinicaL stuDies in aLs
A number of issues complicate clinical studies in ALS, particularly 
with growth factors. In placebo-controlled studies, patients want 
to receive the verum drug, and will often undertake attempts to 
find out whether they receive verum, and then try to obtain the 
drug, or simply discontinue the trial. For growth factors this is 
often easier than for small-molecule drugs (e.g. EPO, IGF-1). This 
might obscure evaluation of the trial in the end. Otherwise, trials 
must be designed in a way that ensures that all patients will receive 
drug at some point, which might limit the rigorousness or power 
of the study (e.g. cross-over design). Moreover, patients might try 
to take part in several studies at once to obtain the maximum of 
possibly disease-modifying new treatments. This might provoke 
interactions between experimental treatments, and obscure treat-
ment effects as well.
Finally, the number of patients available for trials is limited, and 
there are no good surrogate parameters with increased power over 
measures like the ALSFRS that would allow to conduct thorough 
dose-finding studies, implying that the doses tested in large tri-
als have to be chosen by extrapolation from animal efficacy data, 
pharmacokinetics, and safety considerations.
Lessons LearneD
The need for a therapy is urgent. However, urgency should not lead 
to rushed decisions for initiating clinical trials that will be negative 
because necessary key data were lacking. Every negative trial in the 
field will lead to further frustration of physicians, patients, and 
funding agencies, and undermine the most powerful weapon we 
have, hope for finding a real therapeutic option for the patients.
On the pre-clinical side, we need a consensus of what are minimal 
requirements or an assessment strategy for a pre-clinical efficacy 
package. In the field of stroke, this has been done by the so-called 
STAIR (Stroke Therapy Academic Industry Roundtable) criteria 
(Stroke  Therapy  Academic  Industry  Roundtable  II  (STAIR-II) 
2001; Fisher, 2003; Fisher et al., 2005, 2007, 2009; Saver et al., 2009). 
Attempts to do so have been initiated by the ALS TDI with the idea of 
a unified test battery (Scott et al., 2008). However, it is also clear that 
without a precedence of successful translation of pre-clinical data 
to the patient (with the possible exception of Riluzole) it is very dif-
ficult to select strict cut-off criteria for pre-clinical efficacy, as these 
might pose a danger for unwillfully discarding exactly those drugs 
that would have worked in the human. In the absence of proof for 
the predictiveness of all models used, we should use a combination 
of different animal models that monitor different aspects of ALS 
disease pathophysiology, e.g. two different SOD1-mutant models, 
Due to its good tolerability (Morstyn et al., 1988; Nefussy et al., 
2009), its capability to cross the BBB (Schneider et al., 2005; Zhao 
et al., 2007), a clinically translatable dose range, and the initial 
promising hints from the published clinical studies, G-CSF is a 
good candidate for a larger clinical trial in ALS.
GeneraL reasons for cLinicaL faiLures
The demonstration of therapeutic effects of neurotrophic factors 
for various CNS disease conditions did raise great enthusiasm about 
their use as therapeutic agents in the 80’s and early 90’s. Therefore, 
a number of clinical trials in neurodegenerative conditions in the 
peripheral and central nervous system have been conducted. The 
fact that these early studies did not immediately bear striking success 
was likewise received with great disappointment. Today we can bet-
ter weigh the opportunities and pitfalls of growth factor treatment 
in the nervous system, and come to a balanced understanding why 
individual factors have failed, and why others may be successful. 
The clinical failure of growth factors has to be viewed with great 
diligence, and is in no way ascribable to one single reason especially 
in ALS. We have grouped the likely main causative factors below:
seLection of cLinicaL canDiDates was BaseD on insufficient 
pre-cLinicaL efficacy Data
Because of the failure to find clinical efficacy so far, the value of 
pre-clinical data has been questioned. There are two aspects to this 
issue. First, the models used may not be predictive for the work-
ing of a drug in the human system. This is of course an irrefuta-
ble argument, which can’t be proven or disproven in the absence 
of any clinical positive outcome seen so far. This argument has 
in particular been raised with the recent clinical data from the 
minocycline trial where actually the treatment worsened patients’ 
outcome (Couzin, 2007; Gordon et al., 2007b; Carri, 2008; Leigh et 
al., 2008), in contrast to successful treatment of SOD1-transgenic 
mouse models (Kriz et al., 2002; Van Den Bosch et al., 2002; Zhu et 
al., 2002; Zhang et al., 2003). However, before drawing that conclu-
sion it has to be considered that effects of minocycline in conjunc-
tion with the glutamatergic system and interactions with riluzole 
have simply not been studied closely enough before starting the 
trial (Manev and Manev, 2009; Milane et al., 2009).
Second, animal models may be predictive, but have not been 
conducted with sufficient rigorousness and diligence to really tell 
us the truth about efficacy of a drug candidate in the rodent system. 
Reasons for this include insufficient blinding procedures, neglect 
of copy number issues in transgenic models, insufficient number 
of animals used, inadequate statistical methods, and inadequate 
independent replication of study results (Scott et al., 2008).
An example may have been BDNF, where pre-clinical studies 
were done in motoneuron disease models (axotomy, pmn and wob-
bler mice) that were available at the time. After the clinical trial, 
investigations in ALS animal models showed that a BDNF-based 
treatment does not work in the SOD1-transgenic model.
Doses anD/or appLication moDe were inaDequate
For a chronic CNS disease like ALS, the application and dose chosen 
should guarantee a therapeutic level of the drug in the brain and 
spinal cord. For a motoneuron-supportive principle like growth 
factors, the drug level should likely be held constant over time. www.frontiersin.org  June 2010  | Volume 4  | Article 32  |  9
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disadvantage of many of those delivery systems is that it is difficult 
to stop delivery should any serious safety problems emerge. One 
potentially attractive but also difficult delivery method, intrathecal 
delivery, should be further improved as a application route that would 
largely eliminate peripheral adverse effects.
Finally, in clinical trials we should continue to try and identify 
meaningful surrogate parameters that would allow a rational dose-
finding strategy with relatively small patient numbers (e.g. EMG, 
MR tensor imaging, biomarkers). Genome wide association studies 
(GWAS) in sporadic ALS should be intensified to allow genome-based 
subgroup analyses in trials (Dunckley et al., 2007; Schymick et al., 2007; 
Valdmanis et al., 2009). Finally, innovative trial designs that may allow 
to judge early on whether a drug likely has no efficacy (futility designs), 
or smaller trials against cleverly controlled database controls need to be 
further explored (Bryan et al., 2003; Moore and Miller, 2004; Palesch 
and Tilley, 2004; Shefner et al., 2004; Cheung et al., 2006; Czaplinski 
et al., 2006; Gordon et al., 2007a, 2008; Schoenfeld and Cudkowicz, 
2008; Gordon, 2009; Simmons, 2009; Aggarwal et al., 2010).
why are Growth factors stiLL the most rationaL 
approach to aLs?
The  largest  consensus  on  ALS  is  that  its  origin(s)  remain(s) 
unknown despite tremendous work since decades. As long as the 
precise etiopathology(-ies) of the disease is not be known, no 
specific and fully rational therapy can be designed to treat ALS. 
However, in ALS, disease progression is due to the disruption of 
the motor unit, whatever the triggering factor(s) may be. As long 
as we do not have more insights into the disease pathway(s), the 
most rational strategy remains to rescue and to strengthen the 
motor units as a whole, from the neuromuscular junctions up to 
the motoneuron cell body. In that respect, neurotrophic growth fac-
tors are the best tool we have. As detailed before, almost all growth 
factors are able to rescue the motoneuron cell bodies in the spinal 
cord once they reach the CNS.
Despite the considerable number of clinical trials undertaken 
with growth factors in ALS, it appears in retrospect that the hypoth-
esis of growth factors for the treatment of ALS has never really 
been put to test in the human system, as all trials were inadequate 
in dosing and/or application of the protein in question.
There are growth factors with excellent rationale on the shelf, 
that should be evaluated further with stringent criteria. One par-
ticularly interesting group are the hematopoietic growth factors 
EPO and G-CSF: These appear to have many of the above discussed 
properties of nervous growth factors, but may be advantageous with 
regard to the above identified problematic issues. In particular, they 
have an excellent history of safety, a well-known pharmacokinetic 
profile, pass the blood-brain barrier, and the doses efficacious in 
animal models can be easily translated into the clinic.
possibly in mice and rats, and axotomy models. Ideally, a dose-effect 
relationship should be established. All tests have to be conducted 
in a rigorously blinded and randomized manner, and ideally be 
performed in at least two independent labs. If novel animal models 
become available, they should be immediately tested for effects.
In addition, we have to have a very good understanding of 
how the drug in question works, and if it addresses several of the 
mechanisms likely relevant to ALS. For example, growth factors 
should show some efficacy against cell death, both apoptotic and 
excitotoxic, demonstrated on motoneurons, other primary neu-
rons and/or motoneuron lines. Also, effects on the integrity of the 
NMJ should be ascertained. Only VEGF is known to preserve the 
innervations of NMJs in ALS (Zheng et al., 2007). For other growth 
factors, even if there is no direct evidence in an ALS model so far, 
some of them may have a beneficial effect on the NMJs and their 
regeneration, such as G-CSF (Pan et al., 2009), IGF-1 (Apel et al., 
2009) and EPO (Toth et al., 2008). The available mode of action 
and animal model data should then be reviewed by an expert panel 
with the aim to decide whether the evidence package as a whole is 
sufficient to initiate clinical development. This appears advanta-
geous to us in contrast to relying on single strict cut-off criteria, 
as each growth factor has a specific spectrum of activities that in 
each case will generate a blend of mode of actions and animal data 
that have to be appreciated on a case by case basis.
On the pharmacokinetic side, we have to be certain that the 
protein in question passes the BBB, and reaches motoneurons in 
sufficient concentration, and over a reasonable time period. The 
delivery route and formulation need to be fitted to that purpose. 
Measurements of the protein levels in the CSF should be performed 
within the trial. Indeed, drug delivery to the CNS appears to be the 
most crucial problem to address, because pharmacokinetic prob-
lems otherwise preclude to reach a concise conclusion of whether 
a specific growth factor is indeed without effect in ALS trials. This 
appears to be the case with all growth factors that have been tested 
in larger clinical trials (BDNF, CNTF, IGF-1).
Novel delivery tools and application forms should also be explored, 
such as gene therapy with a viral injection or cellular transplants (for 
review, see Hedlund et al., 2007; Bjorklund and Kordower, 2010). 
Those approaches have made progress in terms of safety and efficacy 
at pre-clinical level (Vercelli et al., 2008; Hester et al., 2009; Kim et al., 
2010), and indeed clinical trials with cellular therapies have been 
recently conducted in ALS patients with no major safety concerns 
(Deda et al., 2009; Mazzini et al., 2009). Likewise, viral delivery has 
been explored in patients with Parkinon’s disease (Kaplitt et al., 2007). 
These approaches are promising, but remain much more complicated 
in terms of safety than using pure proteins. The side effects of the 
delivered growth factors have to be well characterized prior to gene 
therapy, with special regard to long term CNS delivery. One principal Frontiers in Neuroscience  |  Neuropharmacology    June 2010  | Volume 4  | Article 32  |  10
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